grant

Metabolism of AMD iPSC-derived RPE

Organization UNIVERSITY OF WASHINGTONLocation SEATTLE, UNITED STATESPosted 30 Sept 2022Deadline 31 Aug 2026
NIHUS FederalResearch GrantFY202421+ years old65 and older65 or older65 years of age and older65 years of age or more65 years of age or older65+ years65+ years oldAdultAdult HumanAffectAge related macular degenerationAge-Related MaculopathyAged 65 and OverAwarenessBiologic ModelsBiological ModelsBlindnessBloodBlood Reticuloendothelial SystemCRISPR correctionCRISPR-based correctionCas9-based correctionCas9-mediated correctionCell Culture TechniquesCell DifferentiationCell Differentiation processCell LineCellLineCellular ExpansionCellular GrowthCharacteristicsComplementComplement ProteinsComplement S-ProteinConsensusConsumptionCulture MediaDataDepositDepositionDevelopmentDiminished VisionDiseaseDisorderDruseDrusenElementsEnergy ExpenditureEnergy MetabolismEnvironmentEpibolinEpithelial CellsExperimental DesignsEye diseasesF-12FutureGenderGenesGenetic AlterationGenetic ChangeGenetic defectGenus HippocampusGlycolysisGoalsHumanIn VitroIndividualIntermediary MetabolismKnowledgeLaboratoriesLow VisionMaintenanceMalignant CellMeasuresMendelian diseaseMendelian disorderMendelian genetic disorderMetabolicMetabolic PathwayMetabolic ProcessesMetabolic dysfunctionMetabolismMitochondriaModel SystemModelingModern ManMorphologyMutationNational Institutes of HealthNutrientOccluding JunctionsOutcomeOuter pigmented layer of retinaOximetryOxygen saturation measurementPartial SightPathogenesisPatientsPersonsPhenotypePhysiologicPhysiologicalPigment cell layer of retinaPigmented layer of retinaPlayPreparationProgenitor CellsRNA SplicingReduced VisionRefrigerant 12RegulationReportingReproducibilityResearch ResourcesResourcesRetinal DiseasesRetinal DisorderRetinal Pigment EpitheliumRetinal pigment epithelial cellsRisk-associated variantRoleSeahorseSerum Spreading FactorSplicingStrains Cell LinesStructureStructure of retinal pigment epitheliumSubnormal VisionSystemTight JunctionsUnited States National Institutes of HealthVariantVariationVisual impairmentVitronectinZonula Occludensabove age 65adulthoodafter age 65age 65 and greaterage 65 and olderage 65 or olderageage dependent macular degenerationage induced macular degenerationage of 65 years onwardage related macular diseaseage related macular dystrophyaged 65 and greateraged 65+aged ≥65cancer cellcell culturecell culturescell growthcellular differentiationcomplementationcultured cell linedesigndesigningdevelopmentaldichlorodifluoromethanedisease phenotypeearly onsetextracellulareye disorderfat metabolismfluorocarbon-12genome mutationgrowth mediahigh riskhuman old age (65+)iPSiPSCiPSCsinduced pluripotent cellinduced pluripotent stem cellinduced pluripotent stem cells derived from patientsinduced pluripotent stem cells from patientsinducible pluripotent stem celllipid metabolismmacular drusenmatrigelmetabolic phenotypemetabolic profilemetabolism measurementmetabolomicsmetabonomicsmetabotypemitochondrialmitochondrial dysfunctionmonogenic diseasemonogenic disorderocular diseaseocular disorderold ageophthalmopathyover 65 yearspatient derived human iPSpatient derived human iPSCpatient derived human induced pluripotent stem cellpatient derived iPSpatient derived iPSCpatient derived induced pluripotent cellspatient derived induced pluripotent stem cellspatient-derived pluripotent stem cellspreparationsretina diseaseretina disorderretinopathyrisk allelerisk generisk genotyperisk locirisk locusrisk variantsenile macular diseasesingle-gene diseasesingle-gene disordersocial rolestem cellstherapeutic targetvision impairmentvision lossvisual lossvisually impaired≥65 years
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary/Abstract
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in adults over

the age of 65 and is expected to affect ~288 million people worldwide by the year 2040. Recently, induced

pluripotent stem cells (iPSC)-derived RPE generated from AMD patients and those with phenotypically similar

monogenic diseases have been shown to approximate elements of AMD disease phenotype in culture,

including the formation of sub-RPE deposits resembling drusen, dysregulated complement, and mitochondrial

dysfunction. Our groups and others have measured metabolite usage, glycolysis, mitochondrial function, and

lipid metabolism in a variety of iPSC RPE model systems. While in vitro RPE models show significant promise

in the discovery of disease mechanisms and therapeutic targets, there is also increasing awareness of

potential limitations, including reproducibility across model systems and fidelity to native conditions. A

comprehensive review of recent iPSC RPE studies shows that the most used traditional culture media are

highly diverse in nutrient and metabolite content which may significantly alter RPE metabolism. Moreover,

multiple types of plating substrates used could contribute to the variability in nutrient environments. A lack of

consensus on baseline nutrient environments and knowledge of their impact on RPE metabolism makes

comparisons between findings challenging. The goal of this proposal is to characterize the metabolic and

disease-relevant phenotypic profiles of AMD iPSC RPE cells in three distinct and commonly used traditional

media and physiological medium closely approximating the composition of human blood. Two AMD iPSC RPE

lines and their CRISPR-corrected isogenic controls will be used in this study. RPE will be differentiated from

one NIH/NYSCF AREDS2 subject iPSC line with multiple known high-risk alleles, selected to gender and

complotype-match RPE lines generated from an individual with early onset macular drusen (EOMD). A splicing

mutation in the CFH gene results in this severe subtype of AMD, and our preliminary data show that EOMD

iPSC RPE display AMD disease-relevant features, including complement dysregulation, sub-RPE deposit

formation, and altered metabolism. iPSC RPE will be cultured on twp substrates (Matrigel®, vitronectin), and

maintained in four media preparations (MEM-α based, DMEM/F-12 based, X-VIVO 10TM and PlasmaxTM). This

project aims to determine the impact of culture microenvironment on AMD and EOMD iPSC RPE metabolism

and disease phenotype. The outcome of this project will be a new and more comprehensive understanding of

how traditional and physiologic media influence the metabolic profile and phenotypic characteristics of normal

and diseased RPE cells. This new understanding will aid in the interpretation of metabolite studies across

model systems and help to inform the design of more physiologic cell culture media for future studies.

Grant Number: 5U01EY034591-03
NIH Institute/Center: NIH

Principal Investigator: Jennifer Chao

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →